BioAtla

BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.

michael burry

Equities

News

Markets

ACIC

AMZN

BABA

BCAB

BIDU

FOUR

GOOG

GOOGL

OLPX

REAL

Michael Burry, the investor renowned for his prescient bet against the housing market before the 2008 financial crisis, has seen his recent wager on Chinese stocks pay significant dividends. 

&#39;Big Short&#39; Investor Michael Burry&#39;s China Bet Pays Off As Top Picks Surge Nearly 60% In 2 Months

Michael Burry illustration by Gonzalo Lanzilotta for Benzinga

Asia

Global

Famed investor Michael Burry, known for his prescient bet against the housing market before the 2008 financial crisis, has made significant changes to his hedge fund&#39;s portfolio in the second quarter of 2024. 

&#39;Big Short&#39; Fame Michael Burry Bets Big On China, Reveals Alibaba As Top Holding — JD.com And Baidu Also Feature On Scion&#39;s Portfolio

Long Ideas

Penny Stocks

Insider Trades

Pre-Market Outlook

Trading Ideas

CRDF

CYAN

XAIR

The Dow Jones index closed higher by around 250 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#39;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Around $2M Bet On This Healthcare Stock? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying

BioAtla Inc

Health Care

Press Releases

BioAtla Presented Data Characterizing Mutated KRAS Genotype and Clinical Outcomes in Patients with Advanced NSCLC Treated with Mecbotamab Vedotin (Mec-V), a CAB-AXL-ADC, at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting

Financing

BioAtla, Inc. Announces Registered Direct Offering to Advance Two Mid-Stage Clinical Programs to Key Inflection Points

BioAtla to Announce Fourth Quarter and Full-Year 2024 Financial Results and Provide Business Highlights on March 27, 2025

BioAtla Announces Two Poster Presentations at Upcoming Medical Meetings

Earnings

BioAtla Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress

BioAtla Announces Upcoming Poster Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

BioAtla Announces Poster Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting

General

BioAtla to Announce First Quarter 2025 Financial Results and Provide Business Highlights on May 6, 2025

BioAtla to Participate in the Citizens Life Sciences Conference

BioAtla Reports First Quarter 2025 Financial Results and Highlights Recent Progress

ALX Oncology Holdings Inc. - Common Stock

ALX Oncology Holdings

Apimeds Pharmaceuticals US, Inc. Common Stock

Apimeds Pharmaceuticals

Burning Rock Biotech Limited - American Depositary Shares

Burning Rock Biotech

CASI Pharmaceuticals, Inc. - Ordinary Shares

CASI Pharmaceuticals

Clene

Chemomab Therapeutics Ltd. - American Depositary Shares

Chemomab Therapeutics

Coeptis Therapeutics Holdings, Inc. - Common Stock

Coeptis Therapeutics

Curis

Cyclacel Pharmaceuticals, Inc. - Common Stock

Cyclacel Pharmaceuticals

Dyadic International, Inc. - Common Stock

Dyadic International

FibroGen

Generation Bio

CytoMed Therapeutics Limited - Ordinary Shares

CytoMed Therapeutics

MiNK Therapeutics

Kezar Life Sciences

Longeveron

Lisata Therapeutics

OnKure Therapeutics, Inc. - Class A Common Stock

OnKure Therapeutics

OSR Holdings

Ovid Therapeutics

Q32 Bio

Radiopharm Theranostics Limited - American Depositary Shares

Radiopharm Theranostics

Tenax Therapeutics

Tempest Therapeutics, Inc. - Common Stock

Tempest Therapeutics

Vor Biopharma

Citizens Capital Markets

JMP Securities

JP Morgan

EF Hutton

BTIG

Comments

BioAtla

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell